
Homepage - RAPT Therapeutics
RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by our mission to treat inflammatory and immunologic diseases. Our cutting-edge science is fully focused on …
About Us - RAPT Therapeutics
RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with …
Pipeline - RAPT Therapeutics
RAPT Therapeutics is focused on the development of therapies for patients with significant unmet needs in inflammatory and immunologic diseases. Utilizing our deep and proprietary expertise …
Press Releases - RAPT Therapeutics, Inc.
RAPT on track to initiate trial this year SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based …
Science - RAPT Therapeutics
Our proprietary drug discovery and development engine has identified several immune drivers that have the ability to be “tuned down” to suppress an overactive immune response in …
RAPT Therapeutics Announces $150 Million Private Placement
Dec 23, 2024 · RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients with significant …
RAPT Therapeutics Deepens Expertise in Allergic Diseases with ...
Apr 15, 2025 · RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients …
RAPT Therapeutics Reports Third Quarter 2025 Financial Results …
Sep 30, 2025 · RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights November 06, 2025 - Initiated prestIgE Phase 2b trial of ozureprubart in food allergy …
Careers - RAPT Therapeutics
At RAPT Therapeutics, we believe in bringing our whole selves to work each day, which requires important work-life balance. We encourage all employees to rejuvenate by sharing …
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 …
Dec 31, 2023 · RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results March 07, 2024 Company maintains solid cash position of $158.9 million SOUTH SAN …